Abstract
Psoriatic disease (PsD), which includes cutaneous psoriasis (PsO) and psoriatic arthritis (PsA), affects 2% of the global population, and results in the development of comorbidities that adversely affect quality of life (QOL) and physical function. Recent advances in the field have allowed for earlier diagnosis of PsD and improved clinical strategies for care, including the use of innovative pathway-specific immune-targeted therapies. Despite these advances, there is no cure for PsD. Ongoing challenges in disease management include the need for adequate treatment response, precision-based care for individual patients, and a better understanding of the interrelationship between the pathogenesis of cutaneous PsO and PsO comorbidities, including PsA. Future progress may arise from integrating clinical disciplines, harnessing artificial intelligence, using molecular dissection to map out the disease pathogenesis of PsA to identify more effective treatment strategies, and exploring the interplay between PsD and comorbidities including cardiovascular disease, obesity, and depression. These developments could lead to personalized treatment approaches and increase the efficacy of therapeutics for PsD, ultimately improving patient outcomes and QOL. This article highlights the presentation of this topic at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2024 annual meeting.